Insider Selling: Artivion (NYSE:AORT) CAO Sells 830 Shares of Stock

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 830 shares of the business’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total value of $29,622.70. Following the completion of the transaction, the chief accounting officer directly owned 127,497 shares in the company, valued at $4,550,367.93. This represents a 0.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amy Horton also recently made the following trade(s):

• On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The shares were sold at an average price of $37.59, for a total value of $65,068.29.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The shares were sold at an average price of $44.42, for a total value of $203,088.24.

Artivion Stock Performance

NYSE:AORT traded up $0.31 during trading on Wednesday, reaching $35.66. The company’s stock had a trading volume of 300,261 shares, compared to its average volume of 399,410. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The firm has a 50 day moving average of $42.51 and a 200-day moving average of $43.14. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of 178.32 and a beta of 1.59.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. The business’s quarterly revenue was up 19.2% on a year-over-year basis. Research analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Artivion

Several institutional investors have recently added to or reduced their stakes in AORT. Aster Capital Management DIFC Ltd boosted its position in shares of Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Artivion in the third quarter worth $27,000. Larson Financial Group LLC raised its stake in Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after purchasing an additional 563 shares in the last quarter. USA Financial Formulas raised its stake in Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after purchasing an additional 703 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on AORT shares. Canaccord Genuity Group reduced their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Needham & Company LLC reiterated a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.